All In Biotech

Drug Trial Radar · NCT02551055

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

32

Actual

Start

Oct 15, 2015

Primary completion

Feb 17, 2017

Study completion Feb 17, 2017

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Sep 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).

Conditions

  • Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Interventions

  • MLN1117Drug

    MLN1117 Tablets

  • TAK-659Drug

    TAK-659 Tablets

  • AlisertibDrug

    Alisertib Tablets

  • PaclitaxelDrug

    Paclitaxel intravenous infusion

  • DocetaxelDrug

    Docetaxel intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1Time frame: Up to Cycle 1 (28 days for MLN1117+TAK-659, MLN1117+Alisertib, MLN1117+Paclitaxel or 21 days for MLN1117+Docetaxel)
  2. Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
  3. Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
  4. Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
  5. Number of Participants With at Least 1 Dose Modification Due to AE in Part 1Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
  6. Overall Response Rate in Part 2Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Lake Success, New York

  • Site not named

    New York, New York

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.